Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Advaxis Inc (NASDAQ:ADXS)

8.46
Delayed Data
As of Feb 24
 -0.11 / -1.28%
Today’s Change
5.23
Today|||52-Week Range
16.30
+18.16%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$339.4M

Company Description

Advaxis, Inc. is a clinical-stage biotechnology company, which intends to develop immunotherapies for cancer and infectious diseases. The company's platform technology is designed to generate a comprehensive immune response by serving as its own adjuvant, directing antigen presentation, increasing tumor infiltrating killer T-cells, and decreasing Tregs/MDSCs in the tumor. Advaxis was founded on June 5, 1987 and is headquartered in Princeton, NJ.

Contact Information

Advaxis, Inc.
305 College Road East
Princeton New Jersey 08540
P:(609) 452-9813
Investor Relations:

Employees

Shareholders

Other institutional35.22%
Mutual fund holders23.75%
Individual stakeholders19.30%

Top Executives

Daniel J. O'ConnorPresident, Chief Executive Officer & Director
Christopher M. DukeChief Operating Officer & Senior Vice President
Sara BonsteinChief Financial Officer & Senior Vice President
Robert G. PetitChief Scientific Officer & Executive VP
Mayo PujolsSenior Vice President-Technical Operations